Novartis | NOVN - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Alcon AG USD 487.4M 0 2026-06
Almirall EUR 214.79M 0 2025-12
Amgen USD 541M 1000K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
Autolus Therapeutics Ltd USD 266.14M 0 2026-03
Bayer EUR 982.42M 0 2026-06
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Fresenius EUR 563.24M 0 2026-06
Fresenius Medical Care EUR 266.11M 3.98M 2026-06
Genmab DKK 61.44M 181K 2026-06
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
GRIFOLS EUR 680.58M 6K 2026-06
Hikma Pharmaceutical USD 221.89M 181.89M 2025-12
J&J USD 2.41B 1.35M 2026-03
Lakefront Biotherapeutics EUR 65.66M 242K 2026-06
Lonza CHF 68.64M 0 2025-12
Merck EUR 434.78M 0 2026-06
Merck USD 2.47B 4.93M 2026-03
Novartis USD 1.9B 7.38M 2026-06
Novartis USD 1.91B 60K 2026-03
Novo Nordisk DKK 4.43B 13.25M 2026-06
Orion EUR 140.87M 0 2026-06
Pfizer USD 5.7B 0 2026-06
Philips EUR 952.02M 729K 2026-03
Recordati EUR 204.81M 1.38M 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.21B 8.25M 2026-03
UCB EUR 190.36M 365.15K 2025-12